Article

Ganciclovir available for ocular herpes

Ganciclovir ophthalmic gel 0.15% (Zirgan, Sirion Therapeutics) is now commercially available for the treatment of acute herpetic keratitis

Tampa, FL

-Ganciclovir ophthalmic gel 0.15% (Zirgan, Sirion Therapeutics) is now commercially available for the treatment of acute herpetic keratitis.

The company began shipping the drug to distributors and retail chains in late April, according to Barry Butler, president and chief executive officer, Sirion Therapeutics.

“Health-care professionals can begin prescribing [ganciclovir] and pharmacies should be able to fill the prescription immediately or within 24 hours if the pharmacy has to order it from their drug distributor,” he said. “We have received an overwhelming number of inquiries regarding [ganciclovir] and its availability and are proud to be providing eye-care professionals with the first innovation in ocular antiviral therapy in the United States in over 30 years.”

The topical ophthalmic gel formulation is supplied in a 5-g polycoated aluminum tube with a white polyethylene tip and cap and protective band.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) Accelerating eye health innovation through CCOI – Stanford Summit
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
© 2025 MJH Life Sciences

All rights reserved.